+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07486089

Study of Dual-Target CAR-NK Cell Therapy for Adults With Advanced or Metastatic HER2-positive and Triple-Negative Breast Cancer

Led by Beijing Biotech · Updated on 2026-03-20

60

Participants Needed

1

Research Sites

56 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an investigational dual-target chimeric antigen receptor natural killer CAR-NK cell therapy in adults with advanced breast cancer, including HER2-positive and triple-negative breast cancer TNBC. This early-phase study aims to test the safety and initial anti-tumor activity of this therapy, which is designed to enhance the immune systems natural ability to recognize and attack tumor cells. The study uses biomarker-guided selection based on tumor antigen expression to assign the most suitable CAR-NK product for each participant. Participants undergo tumor antigen testing using fresh or archival samples to assess HER2ERBB2, MUC1, ROR1, and sometimes mesothelin for TNBC cases. Before receiving the CAR-NK cell infusion, participants receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide. The CAR-NK therapy, given via intravenous infusion, may be administered once or twice depending on safety and clinical status. The study has a dose escalation part to determine a safe dose and an expansion phase to evaluate preliminary effectiveness in groups defined by their tumor markers. During the study, participants are closely monitored for safety and response through clinical and laboratory assessments over up to 24 months. Primary outcomes include dose-limiting toxicities, overall safety profile, and recommended dose determination. Secondary outcomes measure tumor response rates, disease control, duration of response, progression-free survival, and overall survival. Participants also receive supportive care such as premedication and infection prophylaxis as per institutional standards. The total participation duration and follow-up depend on individual response and safety observations.

CONDITIONS

Brief Title

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Research Team

S

Seni S Lu, Phd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here